Opportunity BasketBiotech Construction Completion Fund (BCCF) — Specialized Debt-for-Equity Hybrid Vehicle
A dedicated fund that sources capital from family offices, endowments, and strategic corporate investors specifically for the $10M–$50M final-stage biotech construction gap. The fund deploys capital as a convertible note or revenue-based financing instrument (not dilutive equity) secured against the completed facility and near-term revenue projections from regulatory approval. The fund operator acts as the deal structurer, underwriter, and ongoing asset manager—taking 2% annual management fee + 20% carry on exits.
36 weeks • 70% confidence
Value Proposition
Eliminates the 6–18 month VC fundraising cycle by offering pre-packaged debt structures that don't dilute founders further; investors get security (facility + revenue streams) instead of pure equity bet; fund operator captures carry on successful exits without building a traditional VC firm's overhead.
Target Audience
Biotech firms with FDA approval (or near-certain approval) and 70%+ facility completion; family offices and endowments seeking 8–12% IRR in 3–5 year horizon with lower volatility than early-stage VC
Key Features
- Underwriting focused on facility completion risk + regulatory timeline, not product-market fit
- Revenue-based financing (5–8% of gross revenue until principal + interest repaid) as default structure, avoiding dilution
- Facility appraisal and lien position to secure capital
- And more, with full implementation detail...
Tech Stack
Unlock the full solution
You're seeing a preview. Unlock the complete value proposition, every feature, the full tech stack, the monetization model, and the week-by-week build roadmap, plus a downloadable PDF.
Sign up free to continue3 free solution credits on signup
The build plan is behind the wall
Subscribers get the full monetization model, pricing strategy, and the complete week-by-week roadmap to build this.
Sign up freeOriginal Problem
Biotech companies struggle to secure final-stage funding to complete construction and reach operational capacityBiotech firms with nearly-completed facilities face construction halts when they can't secure final funding rounds, leaving expensive infrastructure incomplete and delaying revenue generation. Companies like Liberation Bioindustries are stuck in a funding gap where traditional investors won't commit to bridge the last $25M needed, forcing them to pause operations and burn cash on idle facilities. Current funding solutions fail because late-stage biotech requires specialized investors who understand the sector's long development timelines and regulatory risks.
Score: 51.2% • 1 payment signal